A review of non-pharmacological and pharmacological management of seasonal and perennial allergic conjunctivitis

Contact Lens and Anterior Eye

Volumn 35, Issue 1, 2012, Pages 9-16

  Bilkhu, Paramdeep S ^a   Wolffsohn, James S ^a   Naroo, Shehzad A ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Allergic conjunctivitis; Management; Medication; Treatment

Indexed keywords

ALLERGEN; ANTAZOLINE; ANTAZOLINE PLUS NAPHAZOLINE; ANTIHISTAMINIC AGENT; AZELASTINE; CATACROM; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DICLOFENAC; DIPHENHYDRAMINE; EMEDASTINE; EPINASTINE; IMMUNOGLOBULIN E; KETOROLAC TROMETAMOL; KETOTIFEN FUMARATE; LODOXAMIDE; LODOXAMIDE TROMETAMOL; LORATADINE; LOTEPREDNOL ETABONATE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; OPTREX; PHENIRAMINE; PLACEBO; RAPITIL; UNCLASSIFIED DRUG; VASOCONSTRICTOR AGENT; XYLOMETAZOLINE;

ALLERGIC CONJUNCTIVITIS; ALLERGY; APPLICATION SITE REACTION; APPLICATION SITE STINGING; BLURRED VISION; BURNING SENSATION; CENTRAL NERVOUS SYSTEM DISEASE; CONTACT LENS; CORNEA DISEASE; DANDER; DERMATOPHAGOIDES; DRUG SAFETY; EYE IRRITATION; GASTROINTESTINAL DISEASE; HAY FEVER; HUMAN; HYPEREMIA; KERATITIS; LYMPHOCYTIC INFILTRATION; MAST CELL; MAST CELL DEGRANULATION; PATHOPHYSIOLOGY; PERENNIAL ALLERGIC CONJUNCTIVITIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; TH2 CELL;

ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS, ALLERGIC; HUMANS; RHINITIS, ALLERGIC, SEASONAL;

EID: 84855970007     PISSN: 13670484     EISSN: 14765411     Source Type: Journal    
DOI: 10.1016/j.clae.2011.08.009     Document Type: Review

References (111)

1. Williams H., Stewart A., von Mutius E., Cookson W., Anderson H.R. Is eczema really on the increase worldwide?. Journal of Allergy and Clinical Immunology 2008, 121:947.
2. Asher M.I., Montefort S., Bjorksten B., Lai C.K.W., Strachan D.P., Weiland S.K., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multi-country cross-sectional surveys. The Lancet 2006, 368(9537):733-743.
3. Savage J., Roy D. Allergic rhinitis: an update. Journal of the Royal Society for the Promotion of Health 2005, 125(4):172-175.
4. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?. Immunology 2004, 112(3):352-363.
5. Cohet C., Cheng S., MacDonald C., Baker M., Foliaki S., Huntington N., et al. Infections, medication use, and the prevalence of symptoms of asthma, eczema and rhinitis in childhood. Journal of Epidemiology and Community Health 2004, 58(10):852-857.
6. Bresciani M., Parisi C., Manghi G., Bonini S. The hygiene hypothesis: does it function worldwide?. Current Opinion in Allergy and Clinical Immunology 2005, 5:147-150.
7. Linneberg A., Jorgenson T., Nielson N.H., Madsen F., Frolund L., Driksen A. The prevalence of skin-test-positive allergic rhinitis in Danish adults: two cross-sectional surveys 8 years apart. The Copenhagen Allergy Study. Allergy 2000, 55(8):767-772.
8. D'Amato G., Cecchi L., Bonini S., Nunes C., Annesi-Maesano I., Behrendt H., et al. Allergenic pollen and pollen allergy in Europe. Allergy 2007, 62(9):976-990.
9. Alcazar P., Carinanos P., De Castro C., Guerra F., Moreno C., Dominguez-Vilches E., et al. Airborne plane-trees (platanus hispanica) pollen distribution in the city of Cordoba, south western Spain, and possible implications on pollen allergy. Journal of Investigative Allergology and Clinical Immunology 2004, 14(3):238-243.
10. Abelson M.B., Leonardi A., Smith L. The mechanisms, diagnosis and treatment of allergy. Review of Ophthalmology 2002, 9(4):74-84.
11. Leonardi A. Emerging drugs for ocular allergy. Expert Opinion on Emerging Drugs 2005, 10(3):505-520.
12. Wolffsohn JS, Naroo SA, Gupta N, Emberlin J. Prevalence and impact of ocular allergy in the population attending UK optometric practice. Contact Lens and Anterior Eye, doi:10.1016/j.clae.2010.12.008.
13. Abelson M.B., Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Survey of Opthalmology 1993, 38(S):115.
14. Friedlaender M.H. Conjunctivitis of allergic origin: clinical presentation and differential diagnosis. Survey of Ophthalmology 1993, 38(S):105.
15. Bielory L. Allergic and immunologic disorders of the eye Part II: ocular allergy. Journal of Allergy and Clinical Immunology 2000, 106(6):1019-1032.
16. Wilson F.M. Adverse external effects of topical ophthalmic medications. Survey of Ophthalmology 1979, 24(2):57-88.
17. Schuman J.S. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clinical Therapeutics 2000, 22(2):167-208.
18. Collet E., Castelain M., Milpied B. Contact allergic reactions on the eyes and eyelids. Revue Francaise D Allergologie 2011, 51(3):318-322.
19. Helm C.J., Holland G.N. Ocular tuberculosis. Survey of Ophthalmology 1993, 38(3):229-256.
20. Donshik P.C., Ehlers W.H., Ballow M. Giant papillary conjunctivitis. Immunology and Allergy Clinics of North America 2008, 28(1):83-103.
21. Bielory L. Ocular allergy treatment. Immunology and Allergy Clinics of North America 2008, 28(1):189-224.
22. Cox L. Allergic conjunctivitis. Allergy and Clinical Immunology International-Journal of the World Allergy Organisation 2007, 19:4-8.
23. Berdy G.J., Berdy S.S. Ocular allergic disorders: disease entities and differential diagnoses. Current Allergy and Asthma Reports 2009, 9(4):297-303.
24. Bielory L. Ocular allergy overview. Immunology and Allergy Clinics of North America 2008, 28(1):1-23.
25. Bonini S., Coassin M., Arroni S., Lambiase A. Vernal keratoconjunctivitis. Eye 2004, 18(4):345-351.
26. Chigbu D.I. The management of allergic eye disease in primary care. Contact Lens and Anterior Eye 2009, 32(6):260-272.
27. Buckley R.J. Allergic eye disease - a clinical challenge. Clinical and Experimental Allergy 1998, 28(6):39-43.
28. Bielory L. Allergic diseases of the eye. Medical Clinics of North America 2006, 90(1):129-148.
29. Pitt A.D., Smith A.F., Lindsell L., Voon L.W., Rose P.W., Bron A.J. Economic and quality of life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiology 2004, 11(1):17-33.
30. Smith A.F., Pitt A.D., Rodruiguez A.E., Alio J.L., Marti N., Teus M., et al. The economic and quality of life impact of seasonal allergic conjunctivitis in Spanish setting. Ophthalmic Epidemiology 2005, 12(4):233-242.
31. Palmares J., Delgado L., Cidade M., Quadrado M.J., Filipe H.P. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. European Journal of Ophthalmology 2010, 20(2):257-264.
32. Hingorani M., Lightman S. Therapeutic options in ocular allergic disease. Drugs 1995, 50(2):208-221.
33. Joss J., Craig T. Seasonal allergic conjunctivitis. Drugs of Today 1998, 34(3):259-265.
34. Bielory B.P., Perez V.L., Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Current Opinion in Allergy and Clinical Immunology 2010, 10(5):469-477.
35. Bacon A.S., Ahluwalia P., Irani A.M., Schwartz L.B., Holgate S.T., Church M.K., et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. Journal of Allergy and Clinical Immunology 2000, 106(5):948-954.
36. Choi S.H., Bielory L. Late-phase reaction in ocular allergy. Current Opinion in Allergy and Clinical Immunology 2008, 8(5):438-444.
37. Ono S.J., Abelson M.B. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. Journal of Allergy and Clinical Immunology 2005, 115(1):118-122.
38. Hodges M.G., Kean-Myers A.M. Classification of ocular allergy. Current Opinion in Allergy and Clinical Immunology 2007, 7(5):424-428.
39. Leonardi A., Motterle L., Bortolotti M. Allergy and the eye. Clinical and Experimental Immunology 2008, 153:17-21.
40. Stahl J.L., Cook E.B., Barney N.P., Graziano F.M. Pathophysiology of ocular allergy: the roles of conjunctival mast cells and epithelial cells. Current Allergy and Asthma Reports 2002, 2(4):332-339.
41. Bonini S.T., Bonini S.E., Berruto A., Tomassini M., Carlesimo S., Bucci M.G., et al. Conjunctival provocation test as a model for the study of allergy and inflammation in humans. International Archives of Allergy and Applied Immunology 1989, 88:144.
42. Ciprandi G., Buscaglia S., Canonica G.W. Management of allergic conjunctivitis. Clinical Immunotherapeutics 1996, 5(5):374-391.
43. Friedlaender M. Overview of ocular allergy treatment. Current Allergy and Asthma Reports 2001, 1(4):375-379.
44. Veys J. Managing the contact lens wearing allergy sufferer. Optician 2004, 5950(227):22-26.
45. Gotzche P.C., Johansen H.K. House dust mite control measures for asthma: systematic review. Allergy 2008, 63(6):646-659.
46. Sheikh A., Hurwitz B., Nurmatov U., van Schayck C.P. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database of Systematic Reviews 2010, 7. CD001563.
47. Eggleston P.A., Wood R.A. Management of allergies to animals. Asthma Proceedings 1992, 13(6):289-292.
48. Bush R.K. Indoor allergens, environmental avoidance and allergic respiratory disease. Allergy and Asthma Proceedings 2008, 29(6):575-579.
49. Wong A.H.C., Barg S.S.N., Leung A.K.C. Seasonal and perennial allergic conjunctivitis. Recent Patents on Inflammation and Allergy Drugs Discovery 2009, 3(2):118-127.
50. Schultz B.L. Pharmacology of ocular allergy. Current Opinion in Allergy and Clinical Immunology 2006, 6(5):383-389.
51. Leino M., Ennevaara K., Latvala A.L., Nordgren P., Posti A.M., Suves R., et al. Double blind group comparative study of 2-percent nedocromil sodium eye drops with 2-percent sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis. Clinical and Experimental Allergy 1992, 22(10):929-932.
52. Blumenthal M., Casale T., Dockhorn R., Jarmoszuk I., Kaiser H., Smith R., et al. Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis. American Journal of Ophthalmology 1992, 113(1):56-63.
53. Cerqueti P.M., Ricca V., Tosca M.A., Buscaglia S., Ciprandi G. Lodoxamide treatment of allergic conjunctivitis. International Archives of Allergy and Immunology 1994, 105(2):185-189.
54. Owen C.G., Shah A., Henshaw K., Smeeth L., Sheikh A. Topical treatments for allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. British Journal of General Practice 2004, 54(503):451-456.
55. BMJ Group and Pharmaceutical Press. British National Formulary 61. 11. Eye. 11.4 Corticosteroids and other anti-inflammatory preparations; 2010. Available from: [accessed 11.04.2011]. http://www.bnf.org/.
56. Juniper E.F., Guyatt G.H., Ferrie P.J., King D.R. Sodium cromoglycate eye drops: regular versus as needed use in seasonal allergic conjunctivitis. Journal of Allergy and Clinical Immunology 1994, 94(1):36-43.
57. Fahy G.T., Easty D.L., Collum L.M., Benedict-Smith A., Hillery M., Parsons D.G. Randomised double masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. European Journal of Ophthalmology 1992, 2:144.
58. Collum L.M.T., Fitzsimon S., Hillery M., Collum A., Power W.J., Pelikan Z., et al. Twice daily 4% sodium cromoglycate vs 2% sodium cromoglycate used four times daily in seasonal (grass pollen) allergic conjunctivitis. Documenta Ophthalmologica 1992, 82(3):267-277.
59. Bielory L., Ghafoor S. Histamine receptors and the conjunctiva. Current Opinion in Allergy and Clinical immunology 2005, 5(5):437-440.
60. Miller J., Wolf E.H. Antazoline phosphate and naphazoline hydrochloride, singly and in combination for the treatment of allergic conjunctivitis - a controlled, double blind clinical trial. Annals of Allergy 1975, 35(2):81-86.
61. Ciprandi G., Buscaglia S., Catrullo A., Pesce G., Fiorino N., Montagna P., et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clinical and Experimental Allergy 1997, 27(2):182-191.
62. Giede-Tuch C., Westhoff M., Zarth A. Azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis - a double blind, randomised, placebo-controlled study. Allergy 1998, 53(9):857-862.
63. Netland P.A., Leahy C., Krenzer K.L. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis in the conjunctival allergen challenge model. American Journal of Ophthalmology 2000, 130(6):717-723.
64. Williams P.B., Crandall E., Sheppard J.D. Azelastine hydrochloride, a dual acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis. Clinical Ophthalmology 2010, 4:993-1001.
65. Canonica G.W., Ciprandi G., Petzold U., Kolb C., Ellers-Lenz B., Hermann R. Topical azelastine in perennial allergic conjunctivitis. Current Medical Research and Opinion 2003, 19(4):321-329.
66. Bielory L., Lien K.W., Bigelson S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005, 65(2):215-228.
67. The electronic Medicines Compendium (eMC). Optrex bloodshot eye drops - summary of product characteristics (SPC); 2010. Available from: [accessed 11.04.11]. http://www.medicines.org.uk/EMC/medicine/23394/SPC/Optrex+Bloodshot+Eye+Drops/.
68. Smith J.P., Lanier B.Q., Tremblay N., Ward R.L., Defaller J.M. Treatment of allergic conjunctivitis with ocular decongestants. Current Eye Research 1982, 2(2):141-147.
69. Lanier B.Q., Tremblay N., Smith J.P., Defaller J.M. A double masked comparison of ocular decongestants as therapy for allergic conjunctivitis. Annals of Allergy 1983, 50(3):174-177.
70. Abelson M.B., Paradis A., George M.A., Smith L.M., Maguire L., Burns R. Effects of vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Archives of Ophthalmology 1990, 108(4):520-524.
71. Abelson M.B., Allansmith M.R., Friedlaender M.H. Effects of topically applied ocular decongestant and antihistamine. American Journal of Ophthalmology 1980, 90:254.
72. Bielory L. Ocular allergy guidelines - a practical treatment algorithm. Drugs 2002, 62(11):1611-1634.
73. Bielory L. Role of antihistamines in ocular allergy. American Journal of Medicine 2002, 113:34-37.
74. Ousler G.W., Workman D.A., Torkildsen G.L. An open label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clinical Therapeutics 2007, 29(4):611-616.
75. Abelson M.B., Kaplan A.P. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10mg and their combination in the human conjunctival allergen challenge model. Clinical Therapeutics 2002, 24(3):445-456.
76. Crampton H.J. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clinical Therapeutics 2003, 25(7):1975-1987.
77. Lanier B.Q., Gross R.D., Marks B.B., Cockrum P.C., Juniper E.F. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Annals of Allergy Asthma and Immunology 2001, 86(6):641-648.
78. Abelson M.B. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Annals of Allergy Asthma and Immunology 1998, 81(3):211-218.
79. Avunduk A.M., Tekelioglu Y., Turk A., Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivitis: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clinical Therapeutics 2005, 27(9):1392-1402.
80. Kidd M., McKenzie S.H., Steven I., Cooper C., Lanz R. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. British Journal of Ophthalmology 2003, 87(10):1206-1211.
81. Abelson M.B., Gomes P., Crampton H.J., Schiffman R.M., Bradford R.R., Whitcup S.M. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clinical Therapeutics 2004, 26(1):35-47.
82. Swamy B.N., Chilov M., McClellan K., Petsoglou C. Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data. Ophthalmic Epidemiology 2007, 14(5):311-319.
83. Tauber J., Raizman M.B., Ostrov C.S., Laibovitz R.A., Abelson M.B., Betts J.G., et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. Journal of Ocular Pharmacology and Therapeutics 1998, 14(2):137-145.
84. Friedlaender M.H. Management of ocular allergy. Annals of Allergy Asthma and Immunology 1995, 75(3):212-222.
85. Bielory L., Friedlaender M.H. Allergic conjunctivitis. Immunology and Allergy Clinics of North America 2008, 28(1):43-58.
86. Dell S.J., Lowry G.M., Northcutt J.A., Howes J., Novack G.D., Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. Journal of Allergy and Clinical Immunology 1998, 102(2):251-255.
87. Ebihara N., Ohashi Y., Uchio E., Okamoto S., Kumagai N., Shoji J., et al. A large, prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. Journal of Ocular Pharmacology and Therapeutics 2009, 25(4):365-371.
88. Miyazaki D., Tominaga T., Kakimaru-Hasegawa A., Nagata Y., Hasegawa J., Inoue Y. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008, 115(6):988-992.
89. Pradalier A., Basset D., Claudel A., Couturier P., Wessel F., Galvain S., et al. Sublingual-swallow immunotherapy (SLIT) with a standardised five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999, 54(8):819-828.
90. Bielory L., Mongia A. Current opinion on immunotherapy for ocular allergy. Current Opinion in Allergy and Clinical Immunology 2002, 2(5):447-452.
91. Skoner D., Gentile D., Bush R., Fasano M.B., McLaughlin A., Esch R.E. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. Journal of Allergy and Clinical Immunology 2010, 125(3):660-666.
92. Lemp M.A. Contact lenses and associated anterior segment disorders: dry eye, blepharitis and allergy. Ophthalmology Clinics of North America 2003, 16(3):463-469.
93. Krohn J.C. A menu of lens wear options for allergy prone patients. Review of Optometry 2000, 137(4):77-80.
94. Wolffsohn JS, Emberlin JC. Role of contact lenses in relieving ocular allergy. Contact Lens and Anterior Eye, doi:10.1016/j.clae.2011.03.004.
95. Lemp M.A. Contact lenses and allergy. Current Opinion in Allergy and Clinical Immunology 2008, 8(5):457-460.
96. Shovlin J.P., DePaolis M., Winn S. Drops to prevent drop outs. Review of Optometry 2000, 137(4):69-75.
97. Brodsky M., Berger W.E., Butrus S., Epstein A.B., Irkec M. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen challenge model. Eye and Contact Lens 2003, 29:113-116.
98. Borazan M., Karalezli A., Akova Y.A., Akman A., Kiyici H., Erbek S.S. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmologica 2009, 87(5):549-554.
99. Lanier B.Q., Finegold I., D'Arienzo P., Granet D., Epstein A.B., Ledgerwood G.L. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Current Medical Research and Opinion 2004, 20(8):1227-1233.
100. Mah F.S., Rosenwasser L.J., Townsend W.D., Greiner J.V., Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Current Medical Research and Opinion 2007, 23(6):1445-1452.
101. Abelson M.B., Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Current Allergy and Asthma Reports 2003, 3(4):363-368.
102. Friedlaender M.H. Conjunctival provocation testing: overview of recent clinical trials in ocular allergy. Current Opinion in Allergy and Clinical Immunology 2002, 2(5):413-417.
103. Ousler G.W., Gomes P.J., Welch D., Abelson M.B. Methodologies for the study of ocular surface disease. Ocular Surface 2005, 3(3):143-154.
104. Spangler D.L., Bensch G., Berdy G.J. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clinical Therapeutics 2001, 23(8):1272-1280.
105. Berdy G.J., Spangler D.L., Bensch G., Berdy S.S., Brusatti R.C. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride ophthalmic solution 0.1% and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival allergen challenge model. Clinical Therapeutics 2000, 22(7):826-833.
106. Abelson M.B., Greiner J.V. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the allergen challenge model. Current Medical Research and Opinion 2004, 20(12):1953-1958.
107. Ciprandi G., Turner D., Gross R.D. Double masked, randomised, parallel-group study comparing olopatadine 0.1% ophthalmic solution with cromolyn sodium 2% and levocabastine 0.05% ophthalmic preparations in children with seasonal allergic conjunctivitis. Current Therapeutic Research 2004, 65(2):186-199.
108. Alexander M., Allegro S., Hicks A. Efficacy and acceptability on nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis. Advances in Therapy 2000, 17(3):140-147.
109. D'Arienzo P.A., Leonardi A., Bensch G. Randomised, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival challenge model. Clinical Therapeutics 2002, 24(3):409-416.
110. Figus M., Fogagnolo P., Lazzeri S., Capizzi F., Romagnoli M., Canovetti A., et al. Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. European Journal of Ophthalmology 2010, 20(5):811-818.
111. Katelaris C.H., Bielory L. Evidence-based study design in ocular allergy trials. Current Opinion in Allergy and Clinical Immunology 2008, 8(5):448-488.